CJC-1295 No DAC vs sermorelin: compare half-life, dosing, IGF-1 effects, and research status so you can see how these two peptides often differ.
CJC-1295 No DAC and sermorelin are both growth hormone-releasing hormone (GHRH) analogs used in research, but they differ mainly in half-life and potency. CJC-1295 No DAC (also known as Mod GRF 1-29) has a half-life of about 30 minutes, while sermorelin's half-life is roughly 10 to 20 minutes. Neither peptide is FDA-approved for general human use in the United States.
Researchers study these peptides to understand how they stimulate pituitary growth hormone (GH) release and affect insulin-like growth factor 1 (IGF-1) levels. The two compounds share a similar mechanism but have distinct pharmacokinetic profiles.
What Are CJC-1295 No DAC and Sermorelin?
CJC-1295 No DAC is a synthetic peptide that mimics GHRH. It contains four amino acid substitutions that make it more resistant to enzymatic breakdown than natural GHRH. This modification extends its half-life compared to sermorelin.
Sermorelin is a 29-amino-acid peptide that matches the first 29 amino acids of human GHRH. It was originally developed as a diagnostic and therapeutic agent for growth hormone deficiency. Sermorelin was formerly FDA-approved under the brand name Geref but is no longer marketed in the US.
Key Differences: Half-Life, Dosing, and Stability
| Feature | CJC-1295 No DAC | Sermorelin |
| Half-life | ~30 minutes | ~10–20 minutes |
| Molecular structure | Modified GHRH (1-29) with 4 substitutions | GHRH (1-29) identical to human sequence |
| Typical research dose | 1–2 mcg/kg | 1–3 mcg/kg |
| Frequency in studies | 1–3 times daily | 1–3 times daily (often more frequent) |
| FDA status | Not FDA-approved | Formerly approved, now discontinued |
Half-life is the biggest practical difference. Sermorelin breaks down quickly, so research protocols often require more frequent administration to maintain stable levels. CJC-1295 No DAC lasts longer but still requires daily dosing in most studies.
Stability also differs. CJC-1295 No DAC is more resistant to DPP-IV enzyme degradation, which contributes to its longer action. Sermorelin is rapidly cleaved by DPP-IV and other peptidases.
How They Affect IGF-1 and Growth Hormone
Both peptides stimulate the pituitary gland to release growth hormone (GH), which then increases insulin-like growth factor 1 (IGF-1) production in the liver. In research settings, CJC-1295 No DAC has been shown to produce a dose-dependent rise in GH and IGF-1.
Sermorelin also raises GH and IGF-1, but its effects are shorter-lived. Clinical studies of sermorelin in children with GH deficiency showed increased growth velocity, which led to its former FDA approval.
Sermorelin was formerly FDA-approved for pediatric growth hormone deficiency but is no longer marketed in the United States.
CJC-1295 No DAC is not FDA-approved for human use in the United States.
Research Status and Safety Considerations
Both peptides are sold as research chemicals for laboratory use only. They are not intended for human consumption, and their long-term safety profiles are not well established. Reported side effects in research subjects include injection site reactions, flushing, headache, and dizziness.
If you search to buy cjc-1295 no dac, you will find many online vendors, but product quality and purity vary widely. Researchers should verify certificates of analysis before purchasing.
Many discussions compare cjc-1295 with dac vs ipamorelin, another GH secretagogue. Ipamorelin is more selective for GH release and does not significantly raise cortisol or prolactin, while CJC-1295 No DAC primarily amplifies GHRH signaling.
Some studies also examine bpc-157 vs cjc 1295 for different research purposes. BPC-157 is investigated for tissue repair, while CJC-1295 No DAC is studied for GH release.
Anecdotal reports on cjc 1295 with dac dosage reddit often describe weekly dosing for the DAC version, but those experiences do not apply to CJC-1295 No DAC. The DAC version has a much longer half-life of about 6–8 days.
For the DAC version, cjc 1295 dac reconstitution guides recommend using bacteriostatic water, but again, this is for research only.
Which One Is More Suitable for Research?
The choice depends on the study design. Sermorelin is useful for short-term, pulsatile GH release experiments. CJC-1295 No DAC is better for sustained GH elevation over several hours.
- Sermorelin: Shorter half-life, more frequent dosing, former clinical use.
- CJC-1295 No DAC: Longer half-life, fewer daily injections, not clinically approved.
- Both: Research-only, not for human use, require professional oversight.
No direct head-to-head clinical trials compare CJC-1295 No DAC and sermorelin in humans. Most available data come from separate studies, so conclusions about relative potency are indirect.
Before considering any peptide for research, consult a healthcare professional and follow institutional guidelines. Self-administration of research peptides carries unknown risks.
Frequently Asked Questions
Is CJC-1295 No DAC the same as sermorelin?
No, they are different peptides. CJC-1295 No DAC has four amino acid substitutions that extend its half-life to about 30 minutes, while sermorelin matches the natural GHRH sequence and has a half-life of 10–20 minutes. Both are GHRH analogs but are not interchangeable in research.
Which is stronger, CJC-1295 No DAC or sermorelin?
In research, CJC-1295 No DAC is often considered more potent because it resists enzymatic breakdown longer, leading to sustained GH release. However, no direct human trials have compared them head-to-head. Relative potency depends on the specific study design and endpoints.
Is sermorelin FDA-approved?
Sermorelin was previously FDA-approved as Geref for pediatric growth hormone deficiency, but it was discontinued in the United States. Currently, sermorelin is not available as an approved prescription drug. It is sold only as a research chemical.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.